-+ 0.00%
-+ 0.00%
-+ 0.00%

IDEXX Q1 FY26 EPS rises 17% to $3.47; revenue climbs 14% to $1.14 billion

PUBT·05/05/2026 10:33:55
Listen to the news
IDEXX Q1 FY26 EPS rises 17% to $3.47; revenue climbs 14% to $1.14 billion
  • IDEXX Laboratories posted first-quarter revenue of USD 1.14 billion, up 14% year over year, while diluted EPS climbed 17% to USD 3.47.
  • Net income attributable to stockholders rose to USD 278.45 million, while operating margin widened 0.1 percentage point to 31.8%.
  • Companion Animal Group revenue increased 15%, led by CAG Diagnostics recurring revenue growth of 14%, while CAG Diagnostics capital instrument revenue jumped 33% on 1,100 IDEXX inVue Dx placements.
  • Jay Mazelsky cited “excellent commercial execution,” adding that IDEXX Cancer Dx momentum is building with a recent international launch and growing U.S. adoption, while inVue Dx Fine Needle Aspiration drew encouraging early customer response.
  • Full-year revenue guidance was raised to USD 4.68 billion-USD 4.76 billion and EPS outlook lifted to USD 14.45-USD 14.90.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained therein.